Artelo Biosciences (ARTL) announced that on February 27, 2026, Artelo’s Board of Directors approved a 3-for-1 reverse stock split of the Company’s common stock. The Company’s common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, March 10, 2026. The Board of Directors determined the 3-for-1 ratio to be appropriate in order to increase the price per share of the Common Stock to improve its marketability and liquidity.

Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions

Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on ARTL:

Disclaimer & DisclosureReport an Issue

Artelo Biosciences reports FY25 EPS ($12.52)

Artelo Biosciences Secures Flexible Multiyear Equity Financing

Artelo Biosciences Granted Nasdaq Extension to Regain Compliance

Artelo Biosciences Shareholders Back Board, Pay and Auditor

Artelo Biosciences faces new Nasdaq compliance challenges